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Several new 2-{[(2E)-3-phenylprop-2-enoyl]amino}benzamides 12aes and 17tev were synthesized by
stirring in pyridine the (E)-3-(2-R1-3-R2-4-R3-phenyl)acrylic acid chlorides 11cek and 11tev with the
appropriate anthranilamide derivatives 10aec or the 5-iodoanthranilic acid 13. Some of the synthesized
compounds were evaluated for their in vitro antiproliferative activity against the full NCI tumor cell line
panel derived from nine clinically isolated cancer types (leukemia, non-small cell lung, colon, CNS,
melanoma, ovarian, renal, prostate and breast). COMPARE analysis, effects on tubulin polymerization in
cells and with puriﬁed tubulin, and effects on cell cycle distribution for 17t, the most active of the series,
indicate that these new antiproliferative compounds act as antitubulin agents.
 2011 Elsevier Masson SAS. All rights reserved.1. Introduction
During a screening program to ﬁnd antiproliferative compounds
in our laboratory’s collection of small organic molecules, the
2-cinnamamido-5-iodobenzamide 1 was found at 10 mM to inhibit
proliferation of the leukemic cell line K562 by 74%.
Compound 1 belongs to cinnamoyl anthranilates, which repre-
sent a class of biologically active substances of great importance in
medicinal chemistry. Tranilast (Rizaben) 2 is an antiallergic drug
approved in 1982 for use in Japan and South Korea for bronchial
asthma and was also investigated for use as an antiproliferative
agent on drug-eluting stents. Its derivative (E)-2-(3-(3,4-dime-
thoxyphenyl)acrylamido)benzamide 3 [1] is another member of
this class of compounds and is more potent than the lead
compound, Tranilast (Fig. 1).
Other biological activities possessed by this class of compounds
are antiﬁbrotic and antinﬂammatory properties [2,3] and inhibition
of cornea pterygium progression and blood vessel development
[4,5]. Finally, cinnamoyl anthranilates are useful for prevention andson SAS. All rights reserved.treatment of glomerular diseases [6] and diseases caused by the
excessive proliferation of vascular intimal cells [7].
However, despite theirwide range of biological activities, a review
of the literature revealed that no anticancer activity had been
described forcinnamoyl anthranilates. Thus, theactivityof compound
1asan inhibitorofK562proliferation ledus to explore thepotential of
this class of compounds as anticancer agents, and we therefore
synthesized a series of novel cinnamoyl anthranilates and screened
the compounds for antileukemic activity. Our work enabled us to
performan initial studyof their structure-activity relationshipsand to
determine their mechanism of action. Compounds 12aes and 17tev
were initially tested in vitro for their antileukemic activity against the
K562 (human chronic myelogenous leukemia) cell line (Table 1).
Among these, 12aec and 17t,u, which showed the best anti-
proliferative activity, were selected by the National Cancer Institute
(NCI) for evaluation in the 60human tumor cell line screen of theNCI.
2. Results and discussion
2.1. Chemistry
A series of 2-{[(2E)-3-phenylprop-2-enoyl]amino}benzamides
12aes and 17tevwas synthesized by stirring the (E)-3-(2-R1-3-R2-
Fig. 1. Structure of cinnamoyl anthranilates.
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priate anthranilamide derivatives 10aec or the 5-iodoanthranilic
acid 13 as described in Schemes 1 and 2.
Crude (E)-3-(2-R1-3-R2-4-R3-phenyl)acrylic acids 11cek,11tev
were obtained by reﬂuxing the appropriately substituted acrylic
acid 8cek, 8tev with thionyl chloride. The 5-methylan-
thranilamide 10a was obtained by reduction of 2-nitro-5-methyl-
benzamideamide 7a as shown in Scheme 1. Compound 7 was
obtained by reaction of the acid 5 with thionyl chloride to afford 6,
followed by treatment of 6 with aqueous ammonia.
The anthranilamide derivatives 10b,c were obtained by stirring
the appropriate 2H-3,1-benzoxazine-2,4(1H)-dione 9b,c in aqueous
ammonia solution (Scheme 1) [8].
A different synthetic method was used to obtain the 2-{[(2E)-3-
phenylprop-2-enoyl]amino}benzamides 17tev (Scheme 2). TheTable 1
Percent growth inhibition obtained with the K562 cell line with compounds at
10 mM and IC50 values (mM) with the same cells.
Com. % inhibition IC50 (mM)
4 14.2 >10
12a 65.4 5.5
12b 64.0 2.5
12c 62.4 5.0
12d 58.0 7.4
12e 28.2 >10
12f 31.0 >10
12g 49.0 10
12h 27.0 >10
12i 52.2 9.5
12j 37.8 >10
12k 64.0 6.3
12l 59.0 8.1
12m 25.5 >10
12n 22.0 >10
12o 46.2 >10
12p 45.9 >10
12q 43.2 >10
12r 43.8 >10
12s 45.9 >10
17t 74.5 0.57
17u 74.1 1.2
17v 26.3 >10
18 63.6 0.02starting materials, 2-cinnamamido-5-iodobenzoic acids 15tev,
were obtained by stirring the 5-iodoanthranilic acid 13 and the
cinnamoyl chlorides 11tev. The reaction gave a mixture of (E)-6-
iodo-2-styryl-4H-benzo[d] [1,3]oxazin-4-ones 14teu and 2-cinna-
mamido-5-iodobenzoic acids 15teu, and themixtures were treated
with aqueous Na3PO4 [9] to give the corresponding acids 15t [10],
15u,v as the only products. By treating the acids 15tev with ethyl
chloroformate, the 2H-3,1-benzoxazine-2,4-diones 16tev were
obtained [11], which, in turn, converted to the 2-{[2E]-3-phenyl-
prop-2-enoylamino}benzamides 17tev by reﬂuxing them in an
aqueous ammonia solution [8].
The structures of the new compounds were determined by
analytical and spectroscopic measurements. In particular, 1H NMR
spectra of compounds 12aes and 17vet were consistent with
an E-oleﬁnic structure. They showed signals attributable to the
b-oleﬁnic protons at 6.66e6.97 d with coupling constants of
16.6e14.7 Hz, as required for E-structures [12], while the a-oleﬁnic
hydrogens were found along with aromatic multiplets. Moreover,
their 1H NMR spectra showed both the NH and NH2 amidic signals;
the cinnamamido NH proton appeared as a singlet at 11.77e11.92 d,
while, according to the literature [13], the presence of an intra-
molecular hydrogen bond renders the benzamido NH2 protons
diastereotopic. Ha is easily exchangeable with D2O and appeared as
a singlet at 8.24e8.44 d. Hb was found at a lower ﬁeld along with
the aromatic multiplets.
2.2. Biology
Synthesized 2-{[(2E)-3-phenylprop-2-enoyl]amino}benza-
mides 12aes and 17tev were initially tested in vitro for their
antileukemic activity against the K562 (human chronic myeloge-
nous leukemia) cell line. Colchicine 18, whose antileukemic activity
is well known, and the 2-cinnamamidobenzamide 4 [13] (Fig. 1),
were used as reference compounds. The percent growth inhibition
at a screening concentration of 10 mM and the IC50 values for
compounds that exhibited at least 50% of growth inhibition at
10 mM are shown in Table 1. Compounds 12aes and 17tev had
inhibitory activity against the K562 cells ranging from 22.0 to 74.5%
at 10 mM, with 12aed,12k,l, and 17t,u (IC50 0.57e8.1 mM) being the
most active compounds. Our data (Table 1) showed positive effects
following substitution with halogens at the 5 position of the ben-
zamido moiety, especially when the substituent was iodine
(compounds 17t and 17u). As far as structure-activity relationships
are concerned, it seems that the introduction of a substituent in
both the benzamido and styryl moieties are favorable for inhibition
of K562 cell growth relative to the unsubstituted 2-cinnamamido-
benzamide 4 (Table 1). However, the best activity was obtained
when the substitutions were present only on the benzamido
moiety (compounds 12aed, 17t). Compounds substituted in both
the benzamido and styryl moieties (compounds 12ees, 17v) were
less active, even if antiproliferative activity was maintained in the
ortho-styryl derivatives (12d,i,l,u).
Compounds 12a,12b,12c,17t and 17uwere evaluated by the NCI
for testing against a panel of approximately 60 human cell lines
derived from seven clinically isolated cancer types (lung, colon,
melanoma, renal, ovarian, brain, and leukemia) according to the NCI
standard protocol [14] (Table 2). The data summarized in Table 2
showed that 12a, 12b, 12c, 17t and 17u caused 50% growth inhibi-
tion at micromolar (12a, 12b, 12c) and submicromolar concentra-
tions (17t, 17u) against every type of tumor cell line investigated.
Moreover, a mean graph midpoint (MG_MID) is calculated for
the GI50, TGI and LC50 parameters, giving an average activity
parameter for all the cell lines. For the calculation of the MG_MID,
insensitive cell lines are included and assigned as their values the
highest concentration tested. Considering the MG_MID values
Scheme 1. Reagents and conditions: (a) SOCl2, reﬂux, 5 h; (b) acetonitrile, aqueous ammonia (25%), reﬂux, 8 h; (c) aqueous ammonia (25%), stirring, rt, 1 h; (d) SnCl2, HCl (35%),
stirring, 0e5 C, (24 h); (e) pyridine, stirring, rt, 24 h.
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17t, at both the GI50 and TGI levels, followed by 17u and 12c.
Compound 17twas selected by the NCI for evaluation in its vivo
toxicity assay, with the ﬁnding that the compound was nontoxic at
a dose of 400 mg/kg in nontumored mice. Compound 17t was also
selected by the NCI for testing in the hollow ﬁber assay, a prelimi-
nary in vivo screening tool, but the compound was not sufﬁciently
active for evaluation in xenograft models.
To predict the probable mechanism of action, the NCI’s bio-
informatic tool COMPARE analysis [15] was performed for the most
active compound 17t. When tested as seed against the NCI “standard
agents” Database, the compound showed Pearson Correlation Coef-
ﬁcients (PCC) of 0.492 and 0.476 at the GI50 level and higher values,
0.677, 0.600, 0.597, at the TGI level. In all cases the highest PCC’swere
with compounds NSC 332598 (rhizoxin), NSC 125973 (paclitaxel),
NSC49842 (vinblastine sulfate) andNSC153858 (maytansine),which
are all antimitotic agents directed against tubulin.
To verify the prediction of the COMPARE algorithm, the effects of
17t on cell cycle distribution as determined by ﬂow cytometry and
on tubulin polymerization were evaluated.
As shown in Fig. 2, 17t caused a dose dependant increase of
K562 cells in the G2-M phase of the cell cycle and a decrease of
cells in G0-G1 after a 24 h treatment. This is the typical ﬂow
cytometric cell cycle distribution observed with drugs targeting
tubulin (see panel b in Fig. 2), which is the main component of the
mitotic spindle.
After 48 h 17t caused extensive apoptosis in K562 cells, with an
AC50 (concentration inducing 50% apoptosis) of 3.7 mM (Fig. 3).
Apoptosis in this experiment was measured as described in the
Experimental Section.To conﬁrm the ability of17t to act onmicrotubules, the percentage
of cells blocked inmitosis (M)wasmorphologically determined after
staining cells with ethidium bromide and acridine orange. The
percentageofK562cells blocked in theMphase after 24hof exposure
to1mM17twas356 (Fig. 4A, untreatedK562cell as control<1%).Of
interest, concentrationsof17thigher than2mMinducedmorphologic
alterations in almost all treated cells, suggesting an interaction
between 17t and the cytoskeleton of K562 cells (Fig. 4C and D).
To examine the effects of 17t on microtubules (tubulin) and
microﬁlaments (actin), PtK2 cells were examined by direct immu-
noﬂuorescence. These cells were selected for this examination
since their ﬂattened morphology yields high quality images of
cytoskeletal elements, particularly the microtubule and microﬁla-
ment networks. As shown in Fig. 5, the microtubules disappeared
while the microﬁlaments persisted with micromolar 17t. In addi-
tion, we found that 17t partially inhibited the polymerization of
puriﬁed tubulin, but this effect was relatively weak, as shown in
Fig. 6, with a comparison to the much stronger inhibition observed
with colchicine 18. With 17t, we observed a concentration depen-
dent inhibition of the rate of microtubule assembly, beginning at
about 10 mM. However, within the concentration range we were
able to examine (up to 40 mM), there was no effect on the extent of
assembly. It should be pointed out that 17t appeared to partially
precipitate at 40 mM. With the classic antitubulin agent colchicine
18, the rate of assembly was 50% inhibited at about 2 mM, and the
extent of assembly at about 5 mM. At 7 and 10 mM colchicine 18,
tubulin polymerization was essentially completely inhibited, an
effect that we were unable to achieve with 17t.
Taken together, our data suggest that 17t interacts with tubulin,
preventing formation of the mitotic spindle and thereby caused
Scheme 2. Reagents and conditions: (a) SOCl2, reﬂux, 5 h; (b) pyridine, stirring, 0e5 C, 24 h; (c) aqueous NaPO3 (0.01 M), reﬂux, 20 h; (d) ethyl chloroformate, acetyl chloride
reﬂux, (15 min þ 30 min); (e) dioxane, acqueous ammonia (25%), reﬂux, 3 h.
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disrupt the integrity of the microtubule cytoskeleton in interphase
cells, causing extensive alterations in cell morphology. Although
its effect on in vitro tubulin assembly is relatively weak, the
cellular effects obtained with 17t are most consistent with those
observed with more potent antitubulin agents. Furthermore,
disruption of cellular microtubules invariably results in activation
of cellular apoptosis.
3. Conclusions
The data reported here show that the 2-{[2E]-3-phenylprop-
2-enoylamino}benzamides 12aes and 17tev caused growth inhi-
bition against many tumor cell lines. The best agents inhibited
proliferation at low micromolar (12a, 12b, 12c) and submicromolar
concentrations (17t,17u) against every tumor cell line investigated.
The best activity was obtained when the 5 position of the benza-
mido moiety was substituted with an iodine atom. COMPARE
analysis, effects on tubulin polymerization in cells and with puri-
ﬁed tubulin, and effects on cell cycle distribution, including
induction of apoptosis, indicate that these new antiproliferative
compounds act as antitubulin agents.4. Experimental
4.1. Chemistry
4.1.1. General
Reaction progress was monitored by TLC on silica gel plates
(Merck 60, F254, 0.2 mm). Organic solutions were dried over
Na2SO4. Evaporation refers to the removal of solvent on a rotary
evaporator under reduced pressure. All melting points were
determined on a Büchi 530 capillary melting point apparatus and
are uncorrected. IR spectra were recorded with a Perkin Elmer
Spectrum RXI FT-IR System spectrophotometer, with compound
as a solid in a KBr disc. 1H NMR spectra were obtained using
a Bruker AC-E 300 MHz spectrometer (tetramethylsilane as
internal standard): chemical shifts are expressed in d values
(ppm). Merck silica gel (Kiesegel 60/230e400 mesh) was used
for ﬂash chromatography columns. Microanalyses data (C, H, N)
were obtained by an Elemental Vario EL III apparatus and were
within 0.4% of the theoretical values. Yields refer to puriﬁed
products and are not optimized. The names of the products were
obtained using the ACD/I-Lab Web service (ACD/IUPAC Name
Free 8.05).
Table 2
Results of multi-dose growth inhibition assay (GI50, mM).
Cell line 12a 12b 12c 17t 17u
Leukemia CCRF-CEM 2.36 2.96 0.429 0.341 0.484
HL-60 (TB) 1.77 1.42 0.346 0.0542 0.165
K-562 1.11 0.845 0.415 0.920 0.370
MOLT-4 3.56 3.95 1.86 0.202 1.42
RPMI-8226 nt 2.79 1.03 0.347 0.772
Non-small cell
lung cancer
A549/ATCC 5.81 3.77 1.02 2.65 1.87
EKVX 5.18 2.83 2.41 0.734 1.00
HOP-62 7.74 3.15 1.51 0.800 2.30
HOP-92 11.4 2.87 1.96 21.2 13.2
NCI-H226 7.28 3.00 2.61 1.09 1.14
NCI-H23 3.38 3.37 1.09 0.840 1.39
NCI-H460 3.59 1.76 0.662 0.453 0.479
NCI-H522 2.83 2.08 nt 0.303 0.459
Colon cancer COLO 205 1.84 1.68 0.917 0.343 0.797
HCC-2998 6.45 0.487 nt 1.25 0.984
HCT-116 3.20 1.98 0.663 0.430 0.509
HCT-15 3.77 2.13 1.04 0.586 0.987
HT29 2.31 1.94 0.527 0.367 0.376
KM12 2.94 1.69 0.739 0.499 0.533
SW-620 3.30 1.99 0.705 0.541 0.605
CNS cancer SF-268 10.9 2.90 1.83 2.31 0.778
SF-295 3.14 1.40 0.625 0.350 0.415
SF539 2.05 2.05 0.819 0.445 0.444
SNB-19 5.69 3.18 2.00 0.586 1.41
SNB75 3.18 1.84 2.07 0.245 1.22
U251 4.13 2.14 0.887 0.501 0.663
Melanoma LOX IMVI 7.65 4.33 3.27 3.75 4.21
MALME-3M 7.59 2.68 1.21 1.60 nt
M14 2.35 1.71 0.482 0.429 0.698
MDA-MB-435 0.660 0.492 0.231 nt 0.234
SK-MEL-2 4.75 2.75 nt 1.40 0.678
SK-MEL-28 5.24 2.88 0.839 2.51 nt
SK-MEL-5 1.01 0.373 0.435 0.383 0.367
UACC-257 17.0 15.1 nt 14.3 38.7
UACC-62 3.77 2.52 0.782 0.632 0.388
Ovarian cancer IGROV1 4.37 3.29 1023 0.917 0.352
OVCAR-3 2.18 1.30 0.349 0.353 0.294
OVCAR-4 11.4 2.77 nt 1.84 2.37
OVCAR-5 8.20 2.74 2.92 3.52 4.02
OVCAR-8 7.49 3.89 nt 1.06 56.0
NCI/ADR-RES 2.79 2.24 0.400 nt 0.719
SK-OV-3 2.79 2.30 1.41 0.744 0.539
Renal cancer 786e0 4.00 2.32 1.76 1.43 0.937
A498 5.56 3.61 1.70 2.70 0.880
ACHN 13.5 4.75 3.36 3.70 9.86
CAKI-1 8.92 0.263 1.34 0.648 0.637
RXF 393 nt 1.71 0.444 3.02 0.425
SN12C 9.63 3.96 2.96 0.635 1.55
TK-10 25.8 5.51 2.67 3.15 26.7
UO-31 9.62 3.57 1.85 3.53 1.63
Prostate cancer PC-3 3.97 3.15 0.684 0.628 0.832
DU-145 3.66 2.16 0.935 0.477 1.28
Breast cancer MCF7 3.48 1.74 0.569 0.450 0.401
MDA-MB-231 7.26 2.48 2.19 0.596 1.41
HS 578T 1.94 2.04 0.624 0.375 0.362
BT-549 4.88 3.19 1.41 9.47 0.816
T-47D 4.20 3.36 1.57 0.857 19.9
MDA-MB-468 3.12 1.17 0.279 nt 0.377
nt ¼ not tested.
GI50 ¼ Growth inhibition of 50%; [(TiTz)/(CTz)]  100 ¼ 50 where
Tz ¼ absorbance at t ¼ 0, Ti ¼ absorbance at t ¼ 48 h, C ¼ absorbance of control at
t ¼ 48 h.
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nitrobenzoyl chloride 6a and 3-phenylacryloyl chlorides 11cek,
11tev
Substituted benzoyl and acryloyl chlorides 6a, 11cek and 11tev
were obtained by reﬂuxing for 5 h the appropriate acid derivatives
5a, 8cek and 8tev (0.01 mol) with thionyl chloride (7.25 ml) [16].
After evaporation under reduced pressure, the crude liquid residue
was used for subsequent reactions without puriﬁcation.4.1.3. Preparation of 5-methyl-2-nitrobenzamide 7a
To 0.01 mol of 5-methyl-2-nitrobenzoyl chloride 6a 10 ml of
aqueous ammonia solution (25%) and 33 ml of acetonitrile were
added. The solution was ﬁrst reﬂuxed for 8 h, then evaporated
under reduced pressure to give pure 7a.
4.1.4. Preparation of 5-methyl-2-aminobenzamide 10a
To a magnetically stirred suspension of stannous chloride
(0.038mol) in concentrated HCl (37%) (15 ml), 0.013mole of 7awas
added at a rate so that the temperature of the slurry was main-
tained below 5 C (about 1 h). After addition was complete, the
mixture was stirred for 24 h. The white slurry thus obtained was
diluted with cold water (150 ml), and aqueous sodium hydroxide
(40%) was added until the tin salt dissolved. The solution was
extracted with ethyl acetate (3  150 ml), and the extracts dried
and evaporated in vacuo to obtain pure 10a.
4.1.5. General procedure for preparation of aminobenzamides 10b,c
A mixture of 0.01 mol of 2H-3,1-benzoxazine-2,4(1H)-diones
9b,c and 25 ml of aqueous ammonia solution (25%) was stirred
for 1 h. The solid precipitate was removed by ﬁltration, washed
with an aqueous ammonia solution (5%) and crystallized from
ethanol.
4.1.6. General procedure for preparation of 2-{[(2E)-3-phenylprop-
2-enoyl]amino}benzamides 12aes
To a cold (0e5 C) stirred suspension of aminobenzamides
10aec (0.016 mol) in pyridine (13 ml), 0.016 mol of the appropriate
3-phenylacryloyl chloride 11cek was added over 30 min. After
addition was complete, the solution was stirred for 24 h and then
poured onto crushed ice. The precipitate was removed by ﬁltration,
washed with water, and crystallized from ethanol.
5-Methyl-2-{[(2E)-3-phenylprop-2-enoyl]amino}benzamide
(12a): yield 85%; mp 228e230 C (dioxane); I.R. (KBr) cm1 3400-
3258 (NH, NH2), 1681, 1651 (2XCO); 1H NMR (DMSO) d 2.31 (s, 3H,
CH3); 6.89 (d, 1H, J ¼ 15.6 Hz, oleﬁnic CH); 7.32e8.49 (a set of
signals, 9H, aromatic protons and NH-H); 7.58 (d, 1H, J ¼ 15.6 Hz,
oleﬁnic CH); 8.24 (s, 1H, NHeH, exchangeable); 11.80 (s, 1H, NH,
exchangeable). Anal. (C17H16N2O2) C,H,N
5-Chloro-2-{[(2E)-3-phenylprop-2-enoyl]amino}benzamides
(12b): yield 67%; mp 218e220 C (dioxane); I.R. (KBr) cm1 3384,
3218 (NH, NH2), 1682, 1659 (2XCO); 1H NMR (DMSO) d 6.83 (d, 1H,
J ¼ 14.9 Hz, oleﬁnic CH); 7.43e8.63 (a set of signals, 10H, aromatic
protons, oleﬁnic CH and NHeH); 8.42 (s, 1H, NHeH, exchangeable);
11.82 (s, 1H, NH, exchangeable). Anal. (C16H13ClN2O2) C,H,N
5-Bromo-2-{[(2E)-3-phenylprop-2-enoyl]amino}benzamides
(12c): yield 98%; mp 229e231 C (dioxane); I.R. (KBr) cm1 3388,
3217 (NH, NH2), 1682, 1659 (2XCO); 1H NMR (DMSO) d 6.82 (d, 1H,
J ¼ 14.9 Hz, oleﬁnic CH); 7.43e8.58 (a set of signals, 10H, aromatic
protons, oleﬁnic CH and NHeH); 8.44 (s, 1H, NHeH, exchangeable);
11.84 (s, 1H, NH, exchangeable). Anal. (C16H13BrN2O2) C,H,N
5-Chloro-2-{[(2E)-3-(2-chlorophenyl)prop-2-enoyl]amino}benza-
mides (12d): yield 36%; mp 268e270 C (dioxane); I.R. (KBr) cm1
3365, 3155 (NH, NH2), 1686, 1661 (2XCO); 1H NMR (DMSO) d 6.90
(d, 1H, J ¼ 15.2 Hz oleﬁnic CH); 7.38e8.63 (a set of signals,
9H, aromatic protons, oleﬁnic CH and NHeH); 8.43 (s, 1H,
NHeH, exchangeable); 11.92 (s, 1H, NH, exchangeable). Anal.
(C16H12Cl2N2O2) C,H,N
5-Chloro-2-{[(2E)-3-(3-chlorophenyl)prop-2-enoyl]amino}benza-
mides (12e): yield 88%; mp 260e261 C (dioxane); I.R. (KBr) cm1
3351, 3157 (NH, NH2), 1681, 1662 (2XCO); 1H NMR (DMSO) d 6.97 (d,
1H, J ¼ 16.6 Hz, oleﬁnic CH); 7.45e8.63 (a set of signals, 9H,
aromatic protons, oleﬁnic CH and NHeH); 8.42 (s, 1H, NHeH,
exchangeable); 11.79 (s, 1H, NH, exchangeable). Anal.
(C16H12Cl2N2O2) C,H,N
Table 3
Overview of the results of the in vitro antitumor screening for compounds 12aec and 17t,u.a
Comp
no. Studiede pGI50b pTGIc pLC50d
no. giving positive
resultse
range MG_MIDf no. giving positive
resultse
range MG_MIDf no. giving positive
resultse
range MG_MIDf
12a 58 58 6.18e4.59 5.36 30 5.53e4.00 4.31 2 4.44e4.00 4.01
12b 58 58 6.58e4.82 5.65 29 6.06e4.00 4.53 7 5.19e4.00 4.06
12c 52 52 6.64e5.47 5.99 23 6.18e4.00 4.58 10 5.02e4.00 4.07
17t 59 59 7.27e4.67 6.05 44 6.41e4.00 4.71 17 4.94e4.00 4.10
17u 57 57 6.78e4.41 5.97 32 6.17e4.00 4.62 8 4.90e4.00 4.05
a Data obtained from the NCI’s in vitro disease-oriented human tumor cells screen.
b pGI50 is the elog of the molar concentration that inhibits 50% net cell growth.
c pTGI is the eLog of the molar concentration giving total growth inhibition.
d pLC50 is the eLog of the molar concentration leading to 50% net cell death.
e Refers to the number of cell lines.
f MG_MID¼mean graphmidpoint¼ arithmetical mean value for all tested cancer cell lines. If the indicated effect was not attainable within the used concentration interval,
the highest tested concentration was used for the calculation.
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mides (12f): yield 58%; mp 243e244 C (dioxane); I.R. (KBr) cm1
3356, 3283, 3177 (NH, NH2), 1675, 1661 (2XCO); 1H NMR (DMSO)
d 6.87 (d, 1H, J ¼ 14.9 Hz, oleﬁnic CH); 7.47e8.62 (a set of signals,Fig. 2. Effects of compound 17t on DNA content/cell following treatment of K562 cells
for 24 h. The cells were cultured without compound (control, a), with an antimitotic
drug used as internal standard (60 nM taxol (b)) and with 1 mM (c), 2 mM (d), or 4 mM
(e) 17t. Cell cycle distribution was analyzed by the standard propidium iodide proce-
dure as described in Materials and Methods. Sub-G0eG1 (A), G0eG1, S, and G2-M cells
are indicated in (a).9H, aromatic protons, oleﬁnic CH and NHeH). 8.43 (s, 1H, NHeH,
exchangeable); 11.82 (s, 1H, NH, exchangeable). Anal.
(C16H12Cl2N2O2) C,H,N
2-{[(2E)-3-(2-bromophenyl)prop-2-enoyl]amino}benzamides
(12g): yield 66%; mp 261e262 C (dioxane); I.R. (KBr) cm1 3366,
3157 (NH, NH2), 1686, 1662 (2XCO); 1H NMR (DMSO) d 6.87 (d, 1H,
J ¼ 14.8 Hz, oleﬁnic CH); 7.35e8.63 (a set of signals, 9H, aromatic
protons, oleﬁnic CH and NHeH); 8.43 (s, 1H, NHeH, exchangeable);
11.90 (s, 1H, NH, exchangeable). Anal. (C16H12BrClN2O2) C,H,N
2-{[(2E)-3-(3-bromophenyl)prop-2-enoyl]amino}benzamides
(12h): yield 91%; mp 251e252 C (dioxane); I.R. (KBr) cm1 3349,
3167 (NH, NH2), 1678, 1662 (2XCO); 1H NMR (DMSO) d 6.96 (d, 1H,
J ¼ 15.1 Hz, oleﬁnic CH); 7.34e8.64 (a set of signals, 9H, aromatic
protons, oleﬁnic CH and NHeH); 8.43 (s, 1H, NHeH, exchangeable);
11.80 (s, 1H, NH, exchangeable). Anal. (C16H12BrClN2O2) C,H,N
5-Chloro-2-{[(2E)-3-(2-methylphenyl)prop-2-enoyl]amino}ben-
zamides (12i): yield 42%; mp 231e232 C (dioxane); I.R. (KBr) cm1
3383, 3165 (NH, NH2), 1687,1660 (2XCO); 1H NMR (DMSO) d 2.34 (s,
3H, CH3); 6.66 (d, 1H, J ¼ 15.6 Hz, oleﬁnic CH); 7.28e8.42 (a set of
signals, 9H, aromatic protons, oleﬁnic CH and NHeH); 8.42 (s, 1H,
NHeH, exchangeable); 11.89 (s, 1H, NH, exchangeable). Anal.
(C17H15ClN2O2) C,H,N
5-Chloro-2-{[(2E)-3-(3-methylphenyl)prop-2-enoyl]amino}ben-
zamides (12j): yield 82%; mp 238e239 C (dioxane); I.R. (KBr) cm1
3337, 3163 (NH, NH2), 1681, 1660 (2XCO); 1H NMR (DMSO) d 2.34 (s,
3H, CH3); 6.80 (d, 1H, J ¼ 15.4 Hz, oleﬁnic CH); 7.21e8.65 (a set of
signals, 9H, aromatic protons, oleﬁnic CH and NHeH); 8.43 (s, 1H,
NHeH, exchangeable); 11.83 (s, 1H, NH, exchangeable). Anal.
(C17H15ClN2O2) C,H,NFig. 3. Percentage of apoptosis induced by compound 17t in K562 cells. Cells were
cultured with different concentrations of 17t. Apoptosis was evaluated after 48 h of
treatment as described in the experimental section. Bars: SE.
Fig. 4. Morphology of K562 cells after 24 h exposure to 2 mM (B), 5 mM (C) and 10 mM (D) compound 17t. (A) Untreated K562 cells (control). Living cells in culture medium were
observed by using a phase contrast invertoscope (40 magniﬁcation).
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zamides (12k): yield 82%; mp 238e239 C (dioxane); I.R. (KBr) cm1
3379, 3212 (NH, NH2),1682,1660 (2XCO); 1H NMR (DMSO) d 2.34 (s,
3H, CH3); 6.78 (d, 1H, J ¼ 15.2 Hz, oleﬁnic CH); 7.23e8.62 (a set of
signals, 9H, aromatic protons, oleﬁnic CH and NHeH); 8.43 (s, 1H,
NHeH, exchangeable); 11.77 (s, 1H, NH, exchangeable). Anal.
(C17H15ClN2O2) C,H,N
5-Bromo-2-{[(2E)-3-(2-chlorophenyl)prop-2-enoyl]amino}benza-
mides (12l): yield 73%; mp 250e251 C (dioxane); I.R. (KBr) cm1
3366, 3153 (NH, NH2), 1685, 1661 (2XCO); 1H NMR (DMSO) d 6.91
(d, 1H, J ¼ 15.1 Hz, oleﬁnic CH); 7.42e8.02 (a set of signals, 9H,
aromatic protons, oleﬁnic CH and NHeH); 8.42 (s, 1H, NHeH,
exchangeable); 11.90 (s, 1H, NH, exchangeable). Anal.
(C16H12BrClN2O2) C,H,N
5-Bromo-2-{[(2E)-3-(3-chlorophenyl)prop-2-enoyl]amino}benza-
mides (12m): yield 56%; mp 260e261 C (dioxane); I.R. (KBr) cm1
3352, 3154 (NH, NH2), 1680, 1662 (2XCO); 1H NMR (DMSO) d 6.97
(d, 1H, J ¼ 16.0 Hz, oleﬁnic CH); 7.45e8.58 (a set of signals,
9H, aromatic protons, oleﬁnic CH and NHeH); 8.44 (s, 1H,
NHeH, exchangeable); 11.81 (s, 1H, NH, exchangeable). Anal.
(C16H12BrClN2O2) C,H,N
5-Bromo-2-{[(2E)-3-(4-chlorophenyl)prop-2-enoyl]amino}benza-
mides (12n): yield 57%; mp 255e256 C (dioxane); I.R. (KBr) cm1
3357, 3285, 3178 (NH, NH2), 1673, 1660 (2XCO); 1H NMR (DMSO)
d 6.87 (d, 1H, J ¼ 14.7 Hz, oleﬁnic CH); 7.47e8.55 (a set of sig-
nals, 9H, aromatic protons, oleﬁnic CH and NHeH); 8.42 (s, 1H,
NHeH, exchangeable); 11.79 (s, 1H, NH, exchangeable). Anal.
(C16H12BrClN2O2) C,H,N
5-Bromo-2-{[(2E)-3-(2-bromophenyl)prop-2-enoyl]amino}benza-
mides (12o): yield 81%; mp 258e259 C (dioxane); I.R. (KBr) cm13366, 3153 (NH, NH2), 1685, 1661 (2XCO); 1H NMR (DMSO) d 6.87
(d, 1H, J ¼ 16.5 Hz, oleﬁnic CH); 7.71e8.52 (a set of signals, 9H,
aromatic protons, oleﬁnic CH and NHeH); 8.42 (s, 1H, NHeH,
exchangeable); 11.88 (s, 1H, NH, exchangeable). Anal.
(C16H12Br2N2O2) C,H,N
5-Bromo-2-{[(2E)-3-(3-bromophenyl)prop-2-enoyl]amino}benza-
mides (12p): yield 81%; mp 258e259 C (dioxane); I.R. (KBr) cm1
3348, 3156 (NH, NH2), 1678, 1661 (2XCO); 1H NMR (DMSO) d 6.97
(d, 1H, J ¼ 15.6 Hz, oleﬁnic CH); 7.35e8.56 (a set of signals, 9H,
aromatic protons, oleﬁnic CH and NHeH); 8.43 (s, 1H, NHeH,
exchangeable); 11.78 (s, 1H, NH, exchangeable). Anal.
(C16H12Br2N2O2) C,H,N
5-Bromo-2-{[(2E)-3-(2-methylphenyl)prop-2-enoyl]amino}ben-
zamides (12q): yield 98%; mp 238e240 C (dioxane); I.R. (KBr) cm1
3384, 3160 (NH, NH2), 1686,1659 (2XCO); 1H NMR (DMSO) d 2.32 (s,
3H, CH3); 6.74 (d, 1H, J ¼ 15.4 Hz, oleﬁnic CH); 7.25e8.56 (a set of
signals, 9H, aromatic protons, oleﬁnic CH and NHeH); 8.42 (s, 1H,
NHeH, exchangeable); 11.89 (s, 1H, NH, exchangeable). Anal.
(C17H15BrN2O2) C,H,N
5-Bromo-2-{[(2E)-3-(3-methylphenyl)prop-2-enoyl]amino}ben-
zamides (12r): yield 71%; mp 268e270 C (dioxane); I.R. (KBr) cm1
3338, 3163 (NH, NH2), 1681, 1661 (2XCO); 1H NMR (DMSO) d 2.34 (s,
3H, CH3); 6.80 (d, 1H, J ¼ 16.5 Hz, oleﬁnic CH); 7.24e8.63 (a set of
signals, 9H, aromatic protons, oleﬁnic CH and NHeH); 8.42 (s, 1H,
NHeH, exchangeable); 11.80 (s, 1H, NH, exchangeable). Anal.
(C17H15BrN2O2) C,H,N
5-Bromo-2-{[(2E)-3-(4-methylphenyl)prop-2-enoyl]amino}ben-
zamides (12s): yield 88%; mp 236e237 C (dioxane); I.R. (KBr) cm1
3353, 3163 (NH, NH2), 1678,1660 (2XCO); 1H NMR (DMSO) d 2.33 (s,
3H, CH3); 6.75 (d, 1H, J ¼ 14.8 Hz, oleﬁnic CH); 7.22e8.56 (a set of
Fig. 5. Panels A, C, E, and G, PtK2 cells stained for tubulin with an antibody to b-tubulin conjugated to Cy3. Panels B, D, F, and H, PtK2 cells stained for actin with an antibody to
b-actin conjugated to FTIC. A and B, untreated cells. C and D, cells treated with 10 mM 17t. E and F, cells treated with 1 mM combretastatin A-4 (a potent antitubulin drug). G and H,
cells treated with 1 mM latrunculin A (a potent inhibitor of actin assembly).
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NHeH, exchangeable); 11.78 (s, 1H, NH, exchangeable). Anal.
(C17H15BrN2O2) C,H,N
4.1.7. General procedure for preparation of 2-cinnamamido-5-
iodobenzoic acids 15tev
To an ice cooled (0e5 C) stirred solution of 2-amino-5-iodo-
benzoic acid 13 (3 mmol) in anhydrous pyridine (20 ml) 2 mmol of
cinnamoyl chlorides 11tevwas added. The solutionwas left stirring
overnight, then poured into cold water. The precipitate was
collected as a mixture of (E)-6-iodo-2-styryl-4H-benzo[d] [1,3]
oxazin-4-ones 14teu and 2-cinnamamido-5-iodobenzoic acids15tev. The mixture was reﬂuxed in 0.01 M aqueous Na3PO4 for
20 h. The solution was allowed to cool to room temperature and,
after ﬁltration, was acidiﬁed with HCl (0.1 M) to pH 2 to give the
corresponding acids 15t [10] and 15u as the only products. Finally,
the precipitate was removed by ﬁltration and washed with cold
chloroform to obtain pure 15t,u. In the case of cinnamoyl chloride
11v, treatment with 2-amino-5-iodobenzoic acid 13 (3 mmol) in
anhydrous pyridine (20 ml) directly gave pure (E)-5-iodo-2-(3-o-
tolylacrylamido)benzoic acid 15v.
(E)-2-(3-(2-chlorophenyl)acrylamido)-5-iodobenzoic acid (15u):
yield 80%; mp 250e252 C (ethanol); I.R. (KBr) cm1 3448, 3117
(NH, OH), 1703, 1688 (2XCO); 1H NMR (DMSO) d 6.94 (d, 1H,
Fig. 6. Comparison of the effects of 17t with those of colchicine as an inhibitor of the
polymerization of puriﬁed tubulin. Assembly was followed in Gilford model 250
recording spectrophotometers equipped with electronic temperature controllers.
Reaction mixtures were preincubated at 30 C without GTP and chilled on ice. GTP
(0.4 mM) was added to the samples, which were transferred to cuvettes held at 0 C.
Baselines were established, and the temperature was jumped to 30 C over about 60 s
and held there for 20 min. Maximal reaction rates and extent of assembly were
determined for each sample and compared to a control reaction mixture in the same
experiment. Each data point was obtained in triplicate, and standard deviations are
shown. Symbols as follows: o, maximum rates obtained with 17t; D, extents of reaction
obtained with 17t; V, maximum rates obtained with colchicine;>, extents of reaction
obtained with colchicine.
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protons, oleﬁnic CH); 11.37 (s, 1H, NHeH, exchangeable); 13.98 (s,
1H, OH, exchangeable). Anal. (C16H11ClINO3) C,H,N
(E)-5-iodo-2-(3-o-tolylacrylamido)benzoic acid (15v): yield 83%;
mp 239e240 C (ethanol); I.R. (KBr) cm1 3353, 3163 (NH, NH2),
1678, 1660 (2XCO); 1H NMR (DMSO) d 2.37 (s, 3H, CH3); 6.82 (d, 1H,
J ¼ 15.3 Hz, oleﬁnic CH); 7.27e8.48 (a set of signals, 8H, aromatic
protons, oleﬁnic CH); 11.28 (s, 1H, NHeH, exchangeable); 13.90 (s,
1H, OH, exchangeable). Anal. (C17H14INO3) C,H,N
4.1.8. General procedure for preparation of 6-iodo-1H-benzo[d]
[1,3]oxazine-2,4-diones 16tev
A mixture of 2-cinnamamido-5-iodobenzoic acids 15tev
(4.6mmol) and ethylchloroformate (25ml) was reﬂuxed for 15min.
After this time, acetyl chloride (1.5 ml) was added, and reﬂux
continued for an additional 30 min. On cooling, the product
precipitated, was removed by ﬁltration, and was washed with
chloroform to give pure 16tev. Compound 16v easily decomposed
and was used as is without puriﬁcation.
1-Cinnamoyl-6-iodo-1H-benzo[d] [1,3] oxazine-2,4-dione (16t):
yield 83%; mp 201e204 C (CHCl3); I.R. (KBr) cm1 1760, 1670
(3XCO); 1H NMR (DMSO) d 6.96 (d, 1H, J ¼ 16 Hz, oleﬁnic CH);
7.39e8.42 (a set of signals, 9H, aromatic protons and oleﬁnic C).
Anal. (C17H10INO4) C,H,N
(E)-1-(3-(2-chlorophenyl)acryloyl)-6-iodo-1H-benzo[d] [1,3]oxa-
zine-2,4-dione (16u): yield 83%; mp 201e204 C (CHCl3); I.R. (KBr)
cm1 1760, 1660 (3XCO); 1H NMR (DMSO) d 7.01 (d, 1H, J ¼ 16 Hz,
oleﬁnic CH); 7.38e8.33 (a set of signals, 8H, aromatic protons and
oleﬁnic C). Anal. (C17H9IClNO4) C,H,N
4.1.9. General procedure for preparation of 2-cinnamamido-5-iodo-
benzamides 17t-v
A solution of 6-iodo-1H-benzo[d] [1,3]oxazine-2,4-diones
16tev (2.3 mmol), 25% aqueous ammonia solution (28 ml) and
dioxane (5 ml) was left under reﬂux for 3 h. After this time, the
solution was kept in a freezer to allow the product to precipitate. It
was removed by ﬁltration and crystallized from dioxane.5-iodo-2-{[(2E)-3-phenylprop-2-enoyl]amino}benzamide (17t):
yield 88%; mp 260e261 C (dioxane); I.R. (KBr) cm1 3393, 3215
(NH, NH2), 1680, 1656 (2XCO); 1H NMR (DMSO) d 6.82 (d, 1H,
J ¼ 15.6 Hz, oleﬁnic CH); 7.43e8.42 (a set of signals, 10H, aromatic
protons, oleﬁnic CH and NHeH); 8.15 (s, 1H, NHeH, exchangeable);
11.80 (s, 1H, NH, exchangeable). Anal. (C16H13IN2O2) C,H,N
5-Iodo-2-{[(2E)-3-(2-chlorophenyl)prop-2-enoyl]amino}benzamides
(17u): yield 88%;mp260e261 C (dioxane); I.R. (KBr) cm13381, 3155
(NH, NH2), 1681, 1660 (2XCO); 1H NMR (DMSO) d 6.97 (d, 1H,
J ¼ 16.6 Hz, oleﬁnic CH); 7.45e8.63 (a set of signals, 9H, aromatic
protons, oleﬁnic CH and NHeH); 8.42 (s, 1H, NHeH, exchangeable);
11.79 (s, 1H, NH, exchangeable). Anal. (C16H12ClIN2O2) C,H,N
5-iodo-2-{[(2E)-3-(2-methylphenyl)prop-2-enoyl]amino}benza-
mide (17v): yield 88%; mp 260e261 C (dioxane); I.R. (KBr) cm1
3368, 3294, 3192 (NH, NH2), 1673, 1658 (2XCO); 1H NMR (DMSO)
d 2.34 (s, 3H, CH3); 6.97 (d,1H, J¼ 16.6 Hz, oleﬁnic CH); 7.45e8.63 (a
set of signals, 9H, aromatic protons, oleﬁnic CH and NHeH); 8.14 (s,
1H, NHeH, exchangeable); 11.77 (s, 1H, NH, exchangeable). Anal.
(C17H15IN2O2) C,H,N
4.2. Biology
4.2.1. Antiproliferative activity
Compounds 12aes and 17tev were initially tested in vitro for
antiproliferative activity against the K562 (human chronic
myelogenous leukemia) cell line. These cell lines were grown at
37 C in a humidiﬁed atmosphere containing 5% CO2, in RPMI-1640
medium supplementedwith 10% fetal bovine serumand antibiotics.
K562 cells were suspended at a density of 1  105 cells/ml in
growthmedium, transferred to a 24-well plate (1ml/well), cultured
with or without (in the case of control wells) a screening concen-
tration of 10 mM compounds and incubated at 37 C for 48 h.
Numbers of viable cells were determined by counting in a hema-
tocytometer after dye exclusion with trypan blue [17]. The anti-
proliferative effects of the compounds were estimated in terms of %
growth inhibition, comparing cell viability of treated and untreated
cells. We determined IC50 values (test agent concentration at
which the cell proliferationwas inhibited by 50% as compared with
the untreated control) for compounds that exhibited the best
activity at the screening concentration.
4.2.2. Tumor cell line screening
The in vitro antiproliferative activity values were obtained by
the Developmental Therapeutics Program, National Cancer Insti-
tute (USA) [18]
The human tumor cell lines of the cancer screening panel are
grown in RPMI 1640 medium containing 5% fetal bovine serum and
2 mM L-glutamine. For a typical screening experiment, cells are
inoculated into 96 well microtiter plates in 100 ml at plating
densities ranging from 5000 to 40,000 cells/well, depending on the
doubling time of the individual cell lines. After cell inoculation, the
microtiter plates are incubated at 37 C, 5% CO2, 95% air and 100%
relative humidity for 24 h prior to addition of experimental drugs.
After 24 h, two plates of each cell line are ﬁxed in situ with TCA, to
represent a measurement of the cell population for each cell line at
the time of drug addition (Tz). Experimental drugs are solubilized
in dimethyl sulfoxide at 400-fold the desired ﬁnal maximum test
concentration and stored frozen prior to use. At the time of drug
addition, an aliquot of frozen concentrate is thawed and diluted to
twice the desired ﬁnal maximum test concentration with complete
medium containing 50 mg/ml gentamicin. Additional four, 10-fold
or ½ log serial dilutions are made to provide a total of ﬁve drug
concentrations plus control. Aliquots of 100 ml of these different
drug dilutions are added to the appropriatemicrotiter wells already
containing 100 ml of medium, resulting in the required ﬁnal drug
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for an additional 48 h at 37 C, 5% CO2, 95% air, and 100% relative
humidity. For adherent cells, the assay is terminated by the addition
of cold TCA. Cells are ﬁxed in situ by the gentle addition of 50 ml of
cold 50% (w/v) TCA (ﬁnal concentration,10% TCA) and incubated for
60 min at 4 C. The supernatant is discarded, and the plates are
washed ﬁve times with tap water and air dried. Sulforhodamine B
(SRB) solution (100 ml) at 0.4% (w/v) in 1% acetic acid is added to
eachwell, and plates are incubated for 10min at room temperature.
After staining, unbound dye is removed by washing ﬁve times with
1% acetic acid, and the plates are air dried. Bound stain is subse-
quently solubilized with 10 mM trizma base, and the absorbance is
read on an automated plate reader at a wavelength of 515 nm. For
suspension cells, the methodology is the same except that the assay
is terminated by ﬁxing settled cells at the bottom of the wells by
gently adding 50 ml of 80% TCA (ﬁnal concentration,16% TCA). Using
the seven absorbance measurements [time zero (Tz), control
growth (C), and test growth in the presence of drug at the ﬁve
concentration levels (Ti)], the percentage growth is calculated at
each of the drug concentration levels. Percentage growth inhibition
is calculated as:
½ðTi TzÞ=ðC TzÞ  100 for concentrations for which Ti  Tz
½ðTi TzÞ=Tz  100 for concentrations for which Ti < Tz
Three dose response parameters are calculated for each
experimental agent. Growth inhibition of 50% (GI50) is calcu-
lated from [(TiTz)/(CTz)]  100 ¼ 50, which is the
drug concentration resulting in a 50% reduction in the net
protein increase (as measured by SRB staining) in control cells
during the drug incubation. The drug concentration resulting in
total growth inhibition (TGI) is calculated from Ti ¼ Tz. The
LC50 (concentration of drug resulting in a 50% reduction in the
measured protein at the end of the drug treatment as compared
to that at the beginning) indicating a net loss of cells follo-
wing treatment is calculated from [(TiTz)/Tz]  100 ¼ 50.
Values are calculated for each of these three parameters if the
level of activity is reached; however, if the effect is not reached
or is exceeded, the value for that parameter is expressed as
greater or less than the maximum or minimum concentration
tested.
4.2.3. Cytotoxicity assays
To evaluate the number of live and dead neoplastic cells, the
cells were stained with trypan blue and counted on a hemocy-
tometer. To determine the growth inhibitory activity of the drugs
tested, 2  105 cells were plated into 25 mm wells (Costar, Cam-
bridge, UK) in 1 ml of complete medium and treated with different
concentrations of each drug. After 48 h of incubation, the number of
viable cells was determined and expressed as percent of control
proliferation.
4.2.4. Morphological evaluation of apoptosis
Drug induced apoptosis was determined morphologically after
labeling with acridine orange and ethidium bromide. Cells
(2  105) were centrifuged (300  g), and the pellet was resus-
pended in 25 ml of the dye mixture. Ten ml of the mixture was
examined under oil immersion with a 100 objective using a ﬂuo-
rescence microscope. Live cells were determined by the uptake of
acridine orange (green ﬂuorescence) and exclusion of ethidium
bromide (red ﬂuorescence) stain. Live and dead apoptotic cells
were identiﬁed by perinuclear condensation of chromatin stained
by acridine orange (100 mg/ml) or ethidium bromide (100 mg/ml),
respectively, and by the formation of apoptotic bodies. Thepercentage of apoptotic cells was determined after counting at least
300 cells.
4.2.5. Determination of apoptosis by annexin-V
Cells (1  106) were washed with phosphate-buffered saline
(PBS) and centrifuged at 200  g for 5 min. Cell pellets were sus-
pended in 100 ml of staining solution containing FITC-conjugated
annexin-V and propidium iodide (Annexine-V-Fluos Staining Kit,
Roche Molecular Biochemicals, Mannheim, Germany) and incu-
bated for 15 min at 20 C. Annexin-V positive cells were evaluated
by ﬂow cytometry (BectoneDickinson.
4.2.6. Flow cytometric analysis of cell cycle and apoptosis
Cells were washed once in ice-cold PBS and resuspended at
1  106 ml in a hypotonic ﬂuorochrome solution containing pro-
pidium iodide (Sigma) 50 mg/ml in 0.1% sodium citrate plus 0.03%
(v/v) nonidet P-40 (Sigma). After 30 min of incubation, the ﬂuo-
rescence of each sample was analyzed as a single-parameter
frequency histogram using a FACScan ﬂow cytometer (Bec-
toneDickinson, San Jose, CA). Distribution of cells in the cell cycle
was determined using the ModFit LT program (Verity Software
House, Inc.). Apoptosis was determined by evaluating the
percentage of hypodiploid nuclei accumulated in the sub-G0eG1
peak after labeling with propidium iodide.
4.2.7. Immunoﬂuorescence
PtK2 cells (Potorus tridactylis kidney epithelial cells) were
obtained from the American Type Tissue Collection and grown as
recommended by the supplier. The technique was described in
detail previously [19,20]. Cells were treated with compounds for
24 h at 37 C prior to ﬁxation and staining with antibodies (Cy3
conjugate of anti-b-tubulin clone TUB2.1 and FTIC conjugate of
anti-b-actin clone Ac-15 monoclonal antibodies from Sigma). Cells
were examined with a Nikon Eclipse E800 microscope equipped
with epiﬂuorescence and appropriate ﬁlters, and images were
collected with a Spot digital camera.
4.2.8. Tubulin assembly
The procedure with puriﬁed bovine brain tubulin was described
in detail previously [21].Acknowledgment
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